Bionor Pharma strengthens its IP-platform in the US

Oslo, 20.05.2011 - Bionor Pharma ASA has today received confirmation of submission of patent applications in the US for its platform technologies.

(Oslo, May 20th 2011)

Bionor Pharma ASA has today received confirmation of submission of patent applications in the US for its platform technologies. This entails establishment of two arms of Intellectual Property Rights which will provide general coverage for future peptide vaccines that induce cellular immunity and humoral immunity, respectively.

The US submissions are follow-ups of the international patent applications of the two platform technologies that were made on December 2nd 2010 and January 6th 2011, respectively.

Bionor Pharma’s technology relates to identification of peptide regions on proteins important for viral replication, followed by modifications of these regions to enhance immune responses. The properties to be protected in the platform patents involve general means to enhance these immune responses. These common properties will be the basis for the development of current and future specific vaccines, which also will be protected by individual product patents.

“Building IP around our vaccine technology will contribute to protect our leading position within modified peptide vaccines and support our freedom to operate, says CEO Henrik Lund. “These patent submissions are among the measures necessary to be well positioned for future out-licensing and commercialization of our vaccine candidates in USA, the most important vaccine market.”

 

Contact information:

Henrik Lund, CEO Bionor Pharma
+47 23 01 09 60
+47 90 97 12 19
hl@bionorpharma.com
 

Rolf Henning Lem, CFO Bionor Pharma
+47 23 01 09 61
+47 97 74 88 45
rhl@bionorpharma.com